Product Description
Kowa is developing Pemafibrate as a treatment for Type 2 Diabetes and Dyslipidemia. (Sourced from: https://clinicaltrials.gov/study/NCT03071692)
Mechanisms of Action: PPAR-a Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Japan | Malaysia
Approved Indications: None
Known Adverse Events: None
Company: Kowa
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Brazil, Bulgaria, Canada, China, Japan, Spain, United States
Active Clinical Trial Count: 16
Highest Development Phases
Phase 3: Dyslipidemia|Hypercholesterolemia|Ischemic Stroke|Myocardial Infarction|Type 2 Diabetes
Phase 2: Biliary Cirrhosis|Cholangitis|Hepatitis, Alcoholic|Liver Cirrhosis|Non-alcoholic Steatohepatitis
Phase 1: Healthy Volunteers|Hyperlipidemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| K-001-201 | P2 |
Unknown Status |
Liver Cirrhosis|Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic |
2026-07-31 |
|
| 2021-003901-23 | P2 |
Active, not recruiting |
Liver Cirrhosis|Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic |
2026-05-04 |
|
| jRCT2071230106 | P2 |
Recruiting |
Cholangitis|Biliary Cirrhosis |
2026-04-08 |
|
| K-001-201 | P2 |
Recruiting |
Liver Cirrhosis|Non-alcoholic Steatohepatitis |
2026-02-01 |